Log In
Print
BCIQ
Print
Print this Print this
 

RI-001

  Manage Alerts
Collapse Summary General Information
Company ADMA Biologics Inc.
DescriptionIV immunoglobulin enriched with respiratory syncytial virus (RSV)-neutralizing antibodies
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic
Latest Stage of DevelopmentPhase II
Standard IndicationPrimary immunodeficiency disease (PIDD)
Indication DetailsTreat primary immunodeficiency disease (PIDD)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today